Nialamide
WikiDoc Resources for Nialamide |
Articles |
---|
Most recent articles on Nialamide |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Nialamide at Clinical Trials.gov Clinical Trials on Nialamide at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Nialamide
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Nialamide Discussion groups on Nialamide Directions to Hospitals Treating Nialamide Risk calculators and risk factors for Nialamide
|
Healthcare Provider Resources |
Causes & Risk Factors for Nialamide |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Nialamide (Niamid, Niamide, Nuredal, Surgex) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was used as an antidepressant.[1] It was withdrawn by Pfizer several decades ago due to the risk of hepatotoxicity.[2][3]
See also
References
- ↑ William Andrew Publishing (1 December 2006). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 2935–. ISBN 978-0-8155-1856-3.
- ↑ Shayne C. Gad (26 April 2012). Safety Pharmacology in Pharmaceutical Development: Approval and Post Marketing Surveillance, Second Edition. CRC Press. pp. 138–. ISBN 978-1-4398-4567-7.
- ↑ Edward Shorter (28 September 2008). Before Prozac : The Troubled History of Mood Disorders in Psychiatry: The Troubled History of Mood Disorders in Psychiatry. Oxford University Press. pp. 137–. ISBN 978-0-19-970933-5.
Template:Antidepressants Template:Monoaminergics Template:Hydrazines